All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
How to approach patients who are MRD positive after initial induction chemotherapy?
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke with Jonathan Canaani, Weill Cornell Medicine, New York, US. We...
The potential of menin-KMT2A inhibitors in the treatment of AML
Here, we summarize six presentations from ASH 2023 discussing the potential of menin-KMT2A inhibitors in the treatment of AML.